Human MDR1 promoter contains an AP-1-binding site [54], and increased AP-1 binding has been observed in several multidrug-resistant cell lines [55], whereas, reduced AP-1 binding has been associated with increased drug sensitivity in other cancer cell lines [56, 57]. This evidence concerns the gene FOS and cancer.